Moderna joins Nasdaq-100 Index replacing Warner Bros

NEW YORK, Oct. 01, 2026 /CourierPR/ -- Moderna, Inc., a biotechnology company, has been announced as a new component of the Nasdaq-100 Index® (NDX®), replacing Warner Bros. Discovery, Inc. The addition of Moderna to the index is expected to have significant implications for the technology and healthcare sectors, as the Nasdaq-100 Index® is designed to track the performance of the largest non-financial companies listed on the Nasdaq Stock Market.

This move signifies a shift in the composition of the Nasdaq-100 Index®, which is a benchmark that encompasses 100 of the largest non-financial companies listed on the Nasdaq Stock Market. The index is closely followed by more than 200 investment products with over $800 billion in assets under management globally. The Nasdaq-100 Index® is a comprehensive suite of rules-based benchmarks and indexes, which includes a wide range of asset classes and geographies.

The inclusion of Moderna, Inc. in the Nasdaq-100 Index® underscores the company's growing prominence in the biotechnology and healthcare sectors. The company's inclusion is expected to bring increased visibility and liquidity to its stock, potentially attracting more investors and increasing the company's market capitalization. This move is likely to have a positive impact on Moderna's stock price and overall market performance.

The Nasdaq-100 Index® is maintained by Nasdaq Global Indexes, a leading index provider that offers a comprehensive suite of rules-based benchmarks and indexes. The company maintains more than 10,000 indexes across various asset classes and geographies. The inclusion of Moderna, Inc. in the index is a testament to the company's commitment to innovation and its leadership in the biotechnology and healthcare sectors.

For additional information on the changes to the Nasdaq-100 Index® and other Nasdaq indexes, investors and analysts can visit the Nasdaq website at indexes.nasdaq.com.